芪苈强心胶囊治疗气虚血瘀型冠心病心绞痛的临床疗效及机制  

Clinical Efficacy and Mechanism of Qiliqiangxin Capsule in the Treatment of Qi Deficiency Blood Stasis Coronary Heart Disease Angina Pectoris

作　　者：牛平平[1] 陈小光 李松[1] 吴焕林[1] 陈佳[1] NIU Ping-ping;CHEN Xiao-guang;LI Song;WU Huan-lin;CHEN Jia(Cardiology Department,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,Guangdong,510120,China;Cardiology Department,The Second Afiliated Hospital ofGuangzhou University of Chinese Medicine,Guangzhou,Guangdong,510120,China)

机构地区：[1]广东省中医院心内科,广东广州510120 [2]广州中医药大学第二附属医院心内科,广东广州510120

出　　处：《现代生物医学进展》2018年第14期2701-2704,2695,共5页Progress in Modern Biomedicine

基　　金：广东省中医药管理局项目(20182040)

摘　　要：目的:探讨芪苈强心胶囊治疗气虚血瘀型冠心病心绞痛的临床疗效及机制。方法:选择我院2015年1月至2017年12月收治的61例气虚血瘀型冠心病心绞痛患者,根据随机数字表法分为观察组(31例)及对照组(30例)。对照组给予基础治疗,观察组在对照组基础上加用芪苈强心胶囊,对比两组治疗前后的血清IL-6水平的变化、治疗后患者的临床疗效、中医症候疗效、心电图疗效及治疗中不良反应的发生情况。结果:治疗后,观察组的临床总有效率(93.5%)、中医症候疗效总有效率(67.7%)、心电图总有效率(93.5%)均显著高于对照组(73.3%、40.0%、70.0%)(P<0.05)。治疗后,两组血清IL-6水平均较治疗前明显下降,且观察组治疗后的血清IL-6水平明显低于对照组(P<0.05)。两组均未发生明显不良反应。结论:芪苈强心胶囊可能通过降低机体血清IL-6水平提高气虚血瘀型冠心病心绞痛的中西医临床症状,改善患者的心功能,且安全性较好。Objective： To investigate the clinical efficacy and mechanism of qiliqiangxin capsule in the treatment of qi deficiency blood stasis coronary heart disease angina pectoris. Methods： From January 2015 to December 2017, 61 cases with qi deficiency blood stasis coronary heart disease angina pectoris in our hospital were chosen and randomly divided into the observation group（31 cases） and the control group（30 cases） according to random numbers table method. The control group was given basic treatment, the observation group was given qiliqiangxin capsule, the clinical efficacy, curative effect of traditional Chinese medicine, ECG efficacy, the changes of serum IL-6 level before and after treatment and incidence of adverse reactions were compared between two groups. Results： After treatment, the total clinical efficacy of observation group（93.5%）, curative effect of traditional Chinese medicine（67.7%） and ECG efficacy of observation group were significantly higher than those of the control group（73.3%, 40.0%, 70.0%）（P〈0.05）. The serum IL-6 levels of two groups after treatment were obviously decreased than those before treatment, while the IL-6 level of observation group was lower than that of the control group（P〈0.05）. No obvious adverse reaction was found in both groups. Conclusions： Qiliqiangxin capsule could effectively enhance the clinical symptoms of Chinese and western medicine in the treatment of qi deficiency blood stasis coronary heart disease angina pectoris, improve the heart function with high safety via decreasing the serum IL-6 level.

关 键 词：芪苈强心胶囊 气虚血瘀型 冠心病心绞痛 临床疗效 

分 类 号：R541.4[医药卫生—心血管疾病]